≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Benign neoplasm: Thymus

DOID EFO Endpoint Browser PheWeb

CD2_BENIGN_THYMUS

thymus neoplasm: A neoplasm that affects the thymus. Representative examples include thymoma and carcinoma.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D15.0&
  • Hospital discharge: ICD-9 — 2126
  • Cause of death: ICD-10 — D15.0&
  • Cause of death: ICD-9 — 2126

2 out of 7 registries used, show all original rules.

82

4. Check minimum number of events

None

82

5. Include endpoints

None

82

6. Filter based on genotype QC (FinnGen only)

77

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D15
Name in latin
Neoplasma benignum thymi

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 372 193 175
Only index persons 325 170 155
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.00
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 58.88 60.91 56.30
Only index persons 57.65 59.27 55.86

-FinnGen-

Key figures

All Female Male
Number of individuals 77 38 39
Unadjusted period prevalence (%) 0.02 0.01 0.02
Median age at first event (years) 63.38 61.56 65.16

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
82
Matched controls
820
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D15.0
ICD-10 Finland
Benign neoplasm: Thymus
+∞
112.5
80
*
D38.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Mediastinum
+∞
38.6
34
*
GEC24
NOMESCO Finland
Thoracoscopic thymectomy
+∞
36.1
32
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
15.1
34.0
41
51
D38.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thymus
+∞
19.5
18
*
8582/3-C37.9
ICD-O-3
Thymoma, type AB of thymus
+∞
17.3
16
*
GEC23
NOMESCO Finland
Transsternal thymectomy
211.2
17.2
17
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
6.8
16.4
38
93
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.3
12.4
64
297
D15.2
ICD-10 Finland
Benign neoplasm: Mediastinum
+∞
11.7
11
*
G70.0
ICD-10 Finland
Myasthenia gravis
125.4
10.7
11
*
N07AA02
ATC
pyridostigmine; systemic
125.4
10.7
11
*
C37
ICD-10 Finland
Malignant neoplasm of thymus
+∞
10.6
10
*
8580/3-C37.9
ICD-O-3
Thymoma, NOS, of thymus
+∞
10.6
10
*
GD1AD
NOMESCO Finland
Thorax CT examination
9.9
9.5
19
24
ZXC96
NOMESCO Finland
Robot assisted procedure
27.7
9.2
12
5
108
Kela drug reimbursment
Myasthenia gravis
99.9
8.6
9
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
19.8
8.4
12
7
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
8.6
8.0
17
24
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.2
6.0
18
51

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
66
327
6.22
11.45
9.2
6.9
1.20
1.21
mmol/l
0.35
59
279
27
67
5.52
11.00
1.3
1.3
—
—
—
0
0
20
38
6.64
10.73
8.8
8.0
—
—
—
0
0
66
343
5.74
10.35
14.0
13.0
1.12
1.24
inr
—
9
102
20
42
5.98
9.66
15.3
9.2
0.64
0.69
%
0.29
20
42
63
337
4.75
8.96
7.5
5.2
0.62
0.58
e9/l
0.52
53
292
48
219
3.87
8.42
2.5
2.5
—
—
—
0
0
19
43
5.45
8.41
15.9
9.1
1.25
1.59
%
0.62
19
43
59
314
4.13
8.14
8.3
5.6
—
—
—
0
0
21
54
4.88
8.02
11.8
8.0
—
—
—
0
0
58
309
4.00
7.90
8.5
5.1
9.37
8.32
%
1.44
58
293
61
337
4.16
7.85
7.6
5.2
0.04
0.04
e9/l
0.38
52
291
59
319
4.03
7.83
8.4
4.9
25.11
27.61
%
1.02
59
301
62
348
4.20
7.76
7.6
5.3
1.67
2.10
e9/l
0.74
54
311
62
350
4.16
7.65
9.5
5.4
0.16
0.20
e9/l
1.46
53
308
57
309
3.77
7.37
8.4
4.8
2.54
2.72
%
0.32
57
290
67
407
4.53
7.25
13.2
8.7
3.94
4.18
e9/l
0.50
58
353
57
312
3.71
7.19
8.2
4.8
60.13
57.35
%
1.11
57
296
55
297
3.59
7.04
8.6
4.7
0.73
0.68
%
0.34
55
278
24
83
3.67
6.09
14.8
7.0
104.12
103.29
mmol/l
0.33
24
83
26
103
3.23
5.28
3.3
2.9
5.95
2.60
e6/l
0.38
13
54
16
47
3.99
5.05
1.4
1.6
0.79
1.26
g/l
1.69
11
42
48
273
2.83
5.03
2.3
2.0
—
—
—
0
0
67
460
3.50
4.90
5.0
4.1
—
—
—
0
0
18
59
3.63
4.87
5.6
4.3
—
—
—
0
0
21
78
3.27
4.69
1.1
1.2
453.33
597.78
titre
—
6
18
16
51
3.66
4.49
10.3
4.1
—
—
—
0
0
43
244
2.60
4.35
4.5
3.6
13.95
47.09
e6/l
1.39
30
171
37
196
2.62
4.30
4.4
4.3
—
—
—
0
0
18
64
3.32
4.29
1.5
1.4
—
—
—
0
0
36
193
2.54
4.03
3.7
3.1
0.14
0.56
e6/l
1.91
27
140
6
5
12.79
3.82
2.7
2.2
30.67
45.18
%
—
6
5
6
5
12.79
3.82
2.5
1.2
0.02
0.18
e9/l
—
6
5
38
214
2.45
3.78
4.0
3.2
18.13
347.59
e6/l
0.54
28
159
48
305
2.38
3.59
11.9
8.6
0.00
0.00
e9/l
0.34
38
252
16
59
3.13
3.57
2.1
2.7
65.64
66.75
g/l
0.27
16
52
8
14
6.20
3.43
2.4
2.8
—
—
—
0
0
13
39
3.76
3.42
7.8
7.8
26.03
25.34
mmol/l
0.38
13
39
33
185
2.31
3.22
4.0
3.0
—
—
—
0
0
19
82
2.71
3.21
1.6
1.4
—
—
—
0
0
6
9
7.08
2.92
1.0
1.1
—
—
—
0
0
35
209
2.18
2.88
2.5
2.1
160.51
184.22
u/l
0.19
35
197
33
195
2.16
2.77
3.1
2.8
—
—
—
0
0
72
583
2.93
2.72
29.1
16.2
15.78
14.87
%
0.57
72
577
20
96
2.43
2.71
2.0
1.7
—
—
—
0
0
23
118
2.32
2.70
2.2
3.2
0.79
0.81
mmol/l
0.38
23
113
5
7
7.51
2.58
1.8
1.6
37.34
25.64
ug/l
—
5
7
18
86
2.40
2.45
1.3
1.3
—
—
—
0
0
25
139
2.15
2.40
2.9
3.1
25.37
149.38
ng/l
1.51
19
113
39
257
1.99
2.37
1.7
1.8
92.34
97.65
pmol/l
0.42
30
120
62
487
2.12
2.23
4.0
3.9
—
—
—
0
0
26
151
2.06
2.22
1.3
1.3
—
—
—
0
0
30
187
1.95
2.09
9.5
5.4
—
—
—
0
0
9
32
3.03
2.07
4.9
4.2
—
—
—
0
0
19
100
2.17
2.07
2.3
2.2
2.34
2.33
g/l
0.04
19
90
29
180
1.95
2.04
3.4
3.3
69.84
50.43
mg/l
0.18
21
118
16
80
2.24
1.96
2.0
1.6
—
—
—
0
0
5
12
4.36
1.85
1.2
1.2
—
—
—
0
0
6
18
3.51
1.78
1.2
1.2
—
—
—
0
0
19
106
2.03
1.78
2.3
2.3
12.32
13.26
umol/l
0.22
19
98
17
91
2.10
1.77
5.1
2.4
1.99
1.61
%
0.91
17
84
15
77
2.16
1.72
1.3
1.4
—
—
—
0
0
14
70
2.21
1.71
1.4
1.6
—
—
—
0
0
10
42
2.57
1.69
1.0
1.6
—
—
—
0
0
22
133
1.89
1.64
1.3
1.5
2.06
2.70
g/l
0.58
15
80
5
14
3.73
1.64
3.0
4.3
—
—
—
0
0
10
44
2.45
1.62
5.1
3.8
5.27
5.04
kpa
—
10
44
45
339
1.73
1.61
4.9
4.7
0.00
0.00
estimate
—
8
64
29
194
1.77
1.57
3.7
3.8
12.97
7.66
mg/mmol
0.28
20
121
7
27
2.74
1.55
1.0
1.1
—
—
—
0
0
5
15
3.48
1.54
1.0
1.7
—
—
—
0
0
18
104
1.94
1.52
1.7
2.0
—
—
—
0
0
45
343
1.69
1.51
3.6
3.6
0.00
0.00
estimate
—
7
61
13
67
2.12
1.48
3.2
2.8
75.03
67.51
e9/l
—
8
52
6
22
2.86
1.46
23.3
3.7
3.62
4.05
mmol/l
—
6
22
23
149
1.76
1.37
1.6
1.4
17.90
22.13
nmol/l
1.00
23
120
71
626
2.00
1.31
4.8
4.5
1.95
1.91
mu/l
0.09
66
557
25
168
1.70
1.31
3.6
3.6
—
—
—
0
0
10
49
2.19
1.28
2.8
2.5
—
—
—
0
0
17
103
1.82
1.25
1.2
1.3
—
—
—
0
0
6
26
2.41
1.21
3.0
3.0
—
—
—
0
0
43
339
1.56
1.16
3.6
3.6
0.00
0.00
estimate
—
8
68
7
30
2.45
1.15
2.6
2.6
—
—
—
0
0
13
74
1.90
1.14
2.5
2.0
92.64
98.08
ug/g
0.05
13
59
7
31
2.37
1.13
2.3
2.4
—
—
—
0
0
7
32
2.30
1.11
7.6
2.7
0.50
0.70
%
—
7
32
7
33
2.22
1.08
1.1
1.3
—
145.08
—
0
15
21
142
1.64
1.06
3.3
3.1
2.46
2.46
mmol/l
0.08
16
123
7
34
2.16
1.05
7.6
2.7
1.16
1.46
%
—
7
34
11
62
1.89
1.00
5.0
5.7
—
—
—
0
0
7
37
1.97
0.96
1.1
1.2
—
—
—
0
0
34
263
1.50
0.96
5.0
3.9
39.18
48.84
ng/l
0.21
27
190
27
199
1.53
0.95
4.6
3.9
—
—
—
0
0
31
236
1.50
0.94
2.6
2.6
59.65
56.68
u/l
0.22
31
220
17
112
1.65
0.94
1.1
1.3
1.18
9.72
u/ml
—
5
54
11
64
1.83
0.91
1.5
1.5
—
—
—
0
0
6
29
2.15
0.91
6.2
4.5
24.23
25.06
mmol/l
—
6
29
8
43
1.95
0.90
1.0
1.3
—
—
—
0
0
6
30
2.08
0.89
30.7
3.8
—
—
—
0
0
8
45
1.86
0.87
7.9
2.9
4.09
4.86
e9/l
—
8
38
10
59
1.79
0.80
5.1
3.5
1.30
0.78
%
—
5
27
9
58
1.62
0.72
8.9
3.3
64.00
86.32
ng/l
—
9
48
0
20
0.00
0.61
0.0
1.5
—
—
—
0
0
56
512
1.30
0.45
3.7
3.9
14.96
15.07
pmol/l
0.10
48
447
8
56
1.47
0.44
1.5
1.3
—
—
—
0
0
8
57
1.45
0.44
1.6
1.4
—
—
—
0
0
11
79
1.45
0.43
1.4
1.3
—
—
—
0
0
6
44
1.39
0.35
2.3
1.6
—
—
—
0
0
9
71
1.30
0.27
1.2
2.8
28.59
8.19
ug/l
—
9
62
17
143
1.24
0.26
1.1
1.2
0.76
1.01
u/ml
—
5
41
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
2.5
—
—
—
0
0
66
683
0.83
0.21
4.4
4.4
4.35
4.64
mmol/l
1.51
61
622
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
8
67
1.21
0.17
6.4
3.8
—
—
—
0
0
20
178
1.16
0.17
3.1
3.1
—
—
—
0
0
21
233
0.87
0.17
3.8
2.8
—
—
—
0
0
67
680
0.92
0.05
4.1
4.4
1.42
1.47
mmol/l
0.48
62
617
27
261
1.05
0.03
5.7
4.5
3.48
2.03
ug/l
0.68
27
227
69
695
0.95
0.00
4.7
5.0
2.43
2.73
mmol/l
2.10
64
632
19
194
0.97
0.00
5.0
3.8
0.00
0.00
estimate
—
7
61
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
12.11
—
0
7
0
6
0.00
-0.00
0.0
1.7
—
1.54
—
0
6
0
6
0.00
-0.00
0.0
1.5
—
8.53
—
0
6
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
155.40
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
205.14
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
0.88
—
0
7

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_THYMUS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_THYMUS.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_THYMUS – Benign neoplasm: Thymus

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data